Investigating the human protein-host protein interactome of SARS-CoV-2 infection in the small intestine
Gastroenterology and Hepatology from Bed to Bench,
20 September 2020
Aim: The present study aimed to identify human protein–host protein interactions of SARS-CoV-2 infection in the small intestine to discern the potential mechanisms and gain insights into the associated biomarkers and treatment strategies.
Background: Deciphering the tissue and organ interactions of the SARS-CoV-2 infection can be important to discern the potential underlying mechanisms. In the present study, we investigated the human protein–host protein interactions in the small intestine.
Methods: Public databases and published works were used to collect data related to small intestine tissue and SARS-CoV-2 infection. We constructed a human protein-protein interaction (PPI) network and showed interactions of host proteins in the small intestine. Associated modules, biological processes, functional pathways, regulatory transcription factors, disease ontology categories, and possible drug candidates for therapeutic targets were identified.
Results: Thirteen primary protein neighbors were found for the SARS-CoV-2 receptor ACE2. ACE2 and its four partners were observed in a highly clustered module; moreover, 8 host proteins belonged to this module. The protein digestion and absorption as a significant pathway was highlighted with enriched genes of ACE2, MEP1A, MEP1B, DPP4, and XPNPEP2. The HNF4A, HNF1A, and HNF1B transcription factors were found to be regulating the expression of ACE2. A significant association with 12 diseases was deciphered and 116 drug-target interactions were identified.
Conclusion: The protein-host protein interactome revealed the important elements and interactions for SARS-CoV-2 infection in the small intestine, which can be useful in clarifying the mechanisms of gastrointestinal symptoms and inflammation. The results suggest that antiviral targeting of these interactions may improve the condition of COVID-19 patients.
Keywords: SARS-CoV-2, small intestine, interactome, protein interaction network, regulatory network, drug targets.
(Please cite as: Khodadoost M, Niknam Z, Farahani M, Razzaghi MR, Norouzinia M. Investigating the human protein-host protein interactome of SARS-CoV-2 infection in the small intestine. Gastroenterol Hepatol Bed Bench 2020;13(4):374-387).
- SARS-CoV-2, small intestine, protein interaction network, regulatory network, drug targets, interactome
Cao W. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. medRxiv 2020. DOI: 10.1101/2020.02.23.20026963
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery 2020;76:71-76.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020;382:1199-207.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet 2020;395:497-506.
Fang Z, Yi F, Wu K, Lai K, Sun X, Zhong N, et al. Clinical characteristics of 2019 coronavirus pneumonia (COVID-19): an updated systematic review. MedRxiv. 2020.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395:507-13.
Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020;47:1275-80.
Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 2020;395:514-23.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
Hamming I, Timens W, Bulthuis M, Lely A, Navis Gv, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-7.
Nikhra V. The Agent and Host Factors in Covid-19: Exploring Pathogenesis and Therapeutic Implications.Biomedical Journal of Scientific & Technical Research. 2020;27: 20669-20681.
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Med 2005;11:875-9.
Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012;487:477-81.
Li Z, Bai T, Yang L, Hou X. Discovery of potential drugs for COVID-19 based on the connectivity map. 2020. DOI:10.21203/rs.2.24684/v1
Feng Z, Wang Y, Qi W. The small intestine, an underestimated site of SARS-CoV-2 infection: from red queen effect to probiotics. Preprints 2020;2020030161.
Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut 2020;69:1141-3.
Zhang H, Li HB, Lyu JR, Lei XM, Li W, Wu G, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis 2020;96:19-24.
Liu X, Yu X, Zack DJ, Zhu H, Qian J. TiGER: a database for tissue-specific gene expression and regulation. BMC Bioinf 2008;9:1-7.
Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circul Res 2020;126:1456-74.
Wicik Z, Eyileten C, Jakubik D, Pavao R, Siller-Matula JM, Postula M. ACE2 interaction networks in COVID-19: a physiological framework for prediction of outcome in patients with cardiovascular risk factors. BioRxiv. 2020. DOI:10.1101/2020.05.13.094714
Karunakaran KB, Balakrishnan N, Ganapathiraju MK. Interactome of SARS-CoV-2/nCoV19 modulated host proteins with computationally predicted PPIs. 2020. DOI: 10.21203/rs.3.rs-28592/v1
Consortium U. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019;47:D506-15.
Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinf 2016;54:1-30.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47:D607-13.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.
Gordon D, Jang G, Bouhaddou M, Xu J, Obernier K, O’Meara M, et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug Repurposing. Nature. 2020;583: 459–468.
Kumar R, Verma H, Singhvi N, Sood U, Gupta V, Singh M, et al. Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Reveals Mosaic Pattern of Phylogeographical Distribution. Msystems 2020;5.
Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:1-11.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinf 2003;4:2.
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017;45:D353-61.
Stöckel D, Kehl T, Trampert P, Schneider L, Backes C, Ludwig N, et al. Multi-omics enrichment analysis using the GeneTrail2 web service. Bioinformatics 2016;32:1502-8.
Matys V, Fricke E, Geffers R, Gößling E, Haubrock M, Hehl R, et al. TRANSFAC®: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003;31:374-8.
Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat Genet 2004;36:431-2.
Brown AS, Patel CJ. A standard database for drug repositioning. Sci Data 2017;4:1-7.
Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data. Nucleic Acids Res 2016;44:D380-4.
Wu J, Deng W, Li S, Yang X. Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci 2020:1-14.
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586-90.
Mönkemüller K, Fry L, Rickes S. Covid-19, Coronavirus, SARS-CoV-2 and the small bowel. Rev Esp Enferm Dig 2020;112:383-8.
Camargo SM, Singer D, Makrides V, Huggel K, Pos KM, Wagner CA, et al. Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. Gastroenterology 2009;136:872-82.
Arnold P, Otte A, Becker-Pauly C. Meprin metalloproteases: molecular regulation and function in inflammation and fibrosis. Biochim Biophys Acta Mol Cell Res 2017;1864:2096-104.
Vazeille E, Bringer MA, Gardarin A, Chambon C, Becker-Pauly C, Pender SL, et al. Role of meprins to protect ileal mucosa of Crohn's disease patients from colonization by adherent-invasive E. coli. PLoS One 2011;6:e21199.
Strollo R, Pozzilli P. DPP4 inhibition: preventing SARS‐CoV‐2 infection and/or progression of COVID‐19? Diabetes Metab Res Rev 2020.
Olivares M, Schüppel V, Hassan AM, Beaumont M, Neyrinck AM, Bindels LB, et al. The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health. Front Microbiol 2018;9:1900.
Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol 2020:1.
Pereira JAdS, Silva FCd, de Moraes-Vieira PMM. The impact of ghrelin in metabolic diseases: an immune perspective. J Diabetes Res 2017;2017.
El-Salhy M. Ghrelin in gastrointestinal diseases and disorders: a possible role in the pathophysiology and clinical implications. Int J Mol Med 2009;24:727-32.
Chen L, Marishta A, Ellison CE, Verzi MP. Identification of transcription factors regulating SARS-CoV-2 entry genes in the intestine. Cell Mol Gastroenterol Hepatol 2020;6:S2352-30129.
Pedersen KB, Chhabra KH, Nguyen VK, Xia H, Lazartigues E. The transcription factor HNF1α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs. Biochim Biophys Acta Mol Cell Res 2013;1829:1225-35.
Barker H, Parkkila S. Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. BioRxiv. 2020. DOI: 10.1101/2020.04.13.038752.
Gendron F-P, Mongrain S, Laprise P, McMahon S, Dubois CM, Blais M, et al. The CDX2 transcription factor regulates furin expression during intestinal epithelial cell differentiation. Am J Physiol Gastrointest Liver Physiol 2006;290:G310-8.
Guo Y, Zeng J, Li Q, Li P, Luo F, Zhang W, et al. Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension. Zhonghua Nei Ke Za Zhi 2020;59:E011-E.
Aly OM. Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID-19 virus main protease. 2020.
chemrxiv. 2020 DOI: 10.26434/chemrxiv.12061302.v1.
Valencia I, Peiró C, Lorenzo Ó, Sánchez-Ferrer CF, Eckel J, Romacho T. DPP4 and ACE2 in diabetes and COVID-19: therapeutic targets for cardiovascular complications? Front Pharmacol 2020;11:1161.
Goto M, Furuta S, Yamashita S, Hashimoto H, Yano W, Inoue N, et al. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport. J Diabetes Invest 2018;9:1261-9.
Elkahloun AG, Saavedra JM. Candesartan could ameliorate the COVID-19 cytokine storm. Biomed Pharmacother 2020:110653.
Wu D, Tang X, Ding L, Cui J, Wang P, Du X, et al. Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. Biomed Pharmacother 2019;116:109040.
Gurwitz D. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics. Drug Dev Res 2020;81:537-40.
Rothlin RP, Vetulli HM, Duarte M, Pelorosso FG. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID‐19. Drug Dev Res 2020;10.
Arab HH, Al-Shorbagy MY, Abdallah DM, Nassar NN. Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease. PLoS One 2014;9:e97193.
Gommans DF, Nas J, Pinto-Sietsma SJ, Koop Y, Konst RE, Mensink F, et al. Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease. Am Heart J 2020;226:60–68.
Skayem C, Ayoub N. Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity. Am J Med Sci 2020;360:300.
Das UN. Bioactive Lipids as Mediators of the Beneficial Action (s) of Mesenchymal Stem Cells in COVID-19. Aging Dis 2020:0.
Castaldo N, Aimo A, Castiglione V, Padalino C, Emdin M, Tascini C. Safety and efficacy of amiodarone in a patient with COVID-19. JACC Case Rep 2020;2:1307-10..
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times